Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 16/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662758 | 0.96 | CHEK2 (0.76) | CHEK2KDM4EALDH1A1MEN1CYP1A2 | |
| SCHEMBL3572190 | 0.93 | CHEK2 (0.71) | CHEK2KDM4EALDH1A1MEN1CYP1A2 | |
| SCHEMBL6643584 | 0.90 | CHEK2 (1.00) | CHEK2 | |
| SCHEMBL3919712 | 0.90 | CHEK2 (0.67) | CHEK2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL3926681 | 0.90 | CHEK2 (0.81) | CHEK2KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL3926677 | 0.89 | CHEK2 (0.83) | CHEK2MEN1KMT2A | |
| SCHEMBL1664788 | 0.89 | CHEK2 (0.68) | CHEK2KDM4EALDH1A1MEN1CYP1A2 | |
| SCHEMBL3565186 | 0.89 | CHEK2 (0.69) | CHEK2KDM4EALDH1A1MEN1CYP1A2 | |
| SCHEMBL3917341 | 0.88 | CHEK2 (0.67) | CHEK2KDM4EALDH1A1MEN1HPGD | |
| SCHEMBL3919705 | 0.88 | CHEK2 (0.67) | CHEK2KDM4EALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435947-B1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-¬4,5|-PYRIDINES AS CDS1/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO MCNEIL PHARM INC (US) | 2007-08-15 | — | — | EP | claimed |
| US-7504414-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504414-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504414-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080009493-A1 | Substituted Benzimidazoles and Imidazo-[4,5]-Pyridines | ARIENTI KRISTEN L | 2008-01-10 | — | — | US | disclosed |
| US-20080009493-A1 | Substituted Benzimidazoles and Imidazo-[4,5]-Pyridines | ARIENTI KRISTEN L | 2008-01-10 | — | — | US | disclosed |
| US-20080009493-A1 | Substituted Benzimidazoles and Imidazo-[4,5]-Pyridines | ARIENTI KRISTEN L | 2008-01-10 | — | — | US | disclosed |
| US-7271261-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271261-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271261-B2 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1435947-B1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-¬4,5|-PYRIDINES AS CDS1/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO MCNEIL PHARM INC (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1435947-B1 | 2-PHENYL BENZIMIDAZOLES AND IMIDAZO-¬4,5|-PYRIDINES AS CDS1/CHK2-INHIBITORS AND ADJUVANTS TO CHEMOTHERAPY OR RADIATION THERAPY IN THE TREATMENT OF CANCER | ORTHO MCNEIL PHARM INC (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | ORTHOMCNEIL PHARMACEUTICAL, INC. | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009493-A1 | Substituted Benzimidazoles and Imidazo-[4,5]-Pyridines | CDKN1A, DDB1, TMBIM6 | CHEK2 14/4885KDM4E 3815/4885ALDH1A1 1427/4885 |
| US-20030176438-A1 | Substituted benzimidazoles and imidazo-[4,5]-pyridines | CDK4, TMBIM6, CDS2 | CHEK2 12/4885KDM4E 2840/4885ALDH1A1 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.